Compare FDMT & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDMT | BTX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.3M | 770.3M |
| IPO Year | 2019 | N/A |
| Metric | FDMT | BTX |
|---|---|---|
| Price | $11.88 | $8.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $28.09 | N/A |
| AVG Volume (30 Days) | ★ 971.2K | 496.2K |
| Earning Date | 11-09-2026 | 11-01-2025 |
| Dividend Yield | N/A | ★ 7.17% |
| EPS Growth | ★ 18.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,209,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $55.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 230194.60 | N/A |
| 52 Week Low | $6.96 | $6.13 |
| 52 Week High | $16.93 | $9.49 |
| Indicator | FDMT | BTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.00 | 40.09 |
| Support Level | $8.68 | $7.73 |
| Resistance Level | $11.96 | $8.51 |
| Average True Range (ATR) | 0.94 | 0.21 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 44.43 | 10.00 |
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
BlackRock Technology and Private Equity Term Trust is a closed-end management investment company. Its investment objectives are to provide total return and income through long-term capital appreciation.